#diabetes

A new UTEP study finds that GLP-1 medications like Ozempic are associated with significantly lower odds of alcohol, opioid, nicotine, and cocaine use disorders, though experts caution against off-label prescribing.

Researchers say new genetic causes of diabetes in babies have been found in non-coding regions of the genome that older studies often overlooked.

A study found that Medicare patients spent less on insulin after a $35 monthly cap took effect in 2023, with evidence that more patients adhered to treatment.

Polymer nanoparticle startup BreezeBio has raised $60 million to advance an mRNA-based therapy for diabetes that uses novel delivery technology to target pancreatic cells. The approach could offer a fundamentally different treatment paradigm for the hundreds of millions living with the disease.

Silicon Valley startup Twin Health is using continuous sensor data and artificial intelligence to build virtual replicas of patients' metabolisms, creating personalized treatment plans that have helped thousands reduce medications and reverse type 2 diabetes symptoms.

A retrospective analysis of 174,000 patients finds tirzepatide users develop diabetic retinopathy at significantly lower rates than matched controls.

Large-scale study finds GLP-1 receptor agonists significantly reduce diabetic retinopathy risk and other eye complications in type 2 diabetes patients.